SSR240612 - Bradykinin Receptor Antagonist - 生命科学试剂 - MedChemExpress_第1页
SSR240612 - Bradykinin Receptor Antagonist - 生命科学试剂 - MedChemExpress_第2页
SSR240612 - Bradykinin Receptor Antagonist - 生命科学试剂 - MedChemExpress_第3页
全文预览已结束

下载本文档

版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领

文档简介

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemESSR240612Cat. No.: HY-15039CAS No.: 464930-42-5分式: CHClNOS分量: 793.41作靶点: Bradykinin Receptor作通路: GPCR/G Protein储存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性数据体外实验 DMSO : 106.6 mg/mL (134.36 mM)* means

2、 soluble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制备储备液1 mM 1.2604 mL 6.3019 mL 12.6038 mL5 mM 0.2521 mL 1.2604 mL 2.5208 mL10 mM 0.1260 mL 0.6302 mL 1.2604 mL请根据产品在不同溶剂中的溶解度,选择合适的溶剂配制储备液,并请注意储备液的保存式和期限。BIOLOGICAL ACTIVITY物活性 SSR240612种有效的,可服的,特异性的肽类缓激肽 B1 (bradykinin B1) 受体拮

3、抗剂,对 bradykininB1 受体(在 MRC5 细胞和表达 B1 受体的 HEK 细胞)的 Ki 值分别为 0.48 nM,0.73 nM;对 B2 受体 (在豚回肠膜和表达 B1 受体的 CHO 细胞) 的 Ki 较弱,分别为 481 nM 和 358 nM。IC50 & Target Ki: 0.48 nM (bradykinin B1 receptor, Human MRC5), 0.73 nM (bradykinin B1 receptor, Human HEK-B1), 481nM (bradykinin B2 receptor, guinea pig ileum membr

4、anes), 358 nM (bradykinin B2 receptor, Human CHO-1/3 Master of Small Molecules 您边的抑制剂师www.MedChemEB2) 1体外研究 SSR240612 is a potent bradykinin B1 receptor antagonist, with Kis of 0.48 nM and 0.73 nM for B2 kininreceptors of human fibroblast MRC5 and HEK cells expressing human B1 receptors, 481 nM and

5、358 nM forB1 receptors of guinea pig ileum membranes and CHO cells expressing human B1 receptor, respectively.SSR240612 inhibits inositol phosphate 1 formation with an IC50 of 1.9 nM, but shows no obvious effect oninositol phosphate-1 formation induced by BK (3 nM) activation of B2 receptor in human

6、 fibroblast MRC5 1.体内研究 SSR240612 (10 mg/kg p.o. or 0.3, 1 mg/kg i.p.) obviously blocks the des-Arg9-BK-induced paw edema in themice. SSR240612 (10 and 30 mg/kg) reduces the duration of the late phase of paw licking in a dosedependent manner in the formalin model of inflammation in mice. SSR240612 (

7、0.3, 3, and 30 mg/kg, p.o.)treatment before capsaicin potently and non-concentration-dependently reduces the ear edema. SSR240612(0.3 mg/kg, i.v.) also suppresses the tissue destruction and neutrophil accumulation in the rat intestine, aftersplanchnic artery occlusion/reperfusion. Moreover, SSR24061

8、2 (1 and 3 mg/kg p.o.) dramacally increasesthe withdrawal latencies in the thermal hyperalgesia induced by UV irradiation in rats 1. SSR240612 inhibitstactile and cold allodynia at 3h in glucose-fed rats but had no effect in control rats with ID50s of 5.5 and 7.1mg/kg, respectively. SSR240612 shows

9、no effect on plasma glucose and insulin, insulin resistance (HOMAindex) and aortic superoxide anion production in glucose-fed rats at 10mg/kg 2.PROTOCOLKinase Assay 1 3HLys0-des-Arg9-BK binding to cell membranes is performed in binding buffer of the following composition:137 mM NaCl, 5.4 mM KCl, 1.0

10、5 mM MgCl2, 1.8 mM CaCl2, 1.2 mM NaH2PO4, 15.5 mM NaHCO3, 10 mMHEPES, 1 g/L bovine serum albumin (BSA), 140 mg/L bacitracin, and 1 M captopril, pH 7.4. Membranes areincubated for 30 min at 25C in 500 L of binding buffer containing 1 nM 3HLys0-des-Arg9-BK forcompetition curves or 0.1 to 10 nM for sat

11、uration isotherms. Filters are washed three times with 5 mL ofbinding buffer, and radioactivity is determined by liquid scintillation spectrometry. Nonspecific binding isdetermined by the addition of 1 M of unlabeled Lys0-des-Arg9BK 1.MCE has not independently confirmed the accuracy of these methods

12、. They are for reference only.Animal Mice 1Administration 1 Groups of eight male albino mice under isoflurane anesthesia receive a 20-L intraplantar injection into theright hind paw of 5 g of IL-1 in phosphate-buffered saline/0.1% BSA. Forty minutes later (T = 0), miceunder anesthesia receive a 20-L

13、 intraplantar injection in the same paw of des-Arg9-BK (10 g/paw) inwater. SSR240612 or vehicle 5% (v/v) ethanol and 5% (v/v) Tween 80 in water is administered by oral routeat the doses of 1, 3, and 10 mg/kg 1 h before des-Arg9-BK injection and by intraperitoneal route at the dosesof 0.1, 0.3, and 1

14、 mg/kg 40 min before des-Arg9-BK injection. Paw volume is measured with aplethysmometer at T = -2 h (initial measurement) and at several times after edema induction (T = 20, 40, 60,and 120 min). Paw edema volume is expressed in milliliters as the difference between the paw volume ateach time after e

15、dema induction and the initial paw volume. Results for each group are expressed as mean S.E.M. of individual paw edema volumes. Statistical analysis is performed after verification of normality andhomogeneity of variances using repeated ANOVA, then Duncans test, treated groups versus des-Arg9-BKcont

16、rol group 1.2/3 Master of Small Molecules 您边的抑制剂师www.MedChemERats 1SSR240612 (suspended with 0.1% Tween 80 in saline) is administered by the oral route in a volume of 20mL/kg, 2 h before the thermal hyperalgesia measurement. In the time course study, the compound isadministered at 3 mg/kg p.o. 0.08,

17、 0.25, 0.5, 1, 2, 4, 6, 8, and 24 h before measuring the withdrawal latenciesin rats. Results are expressed in seconds as mean withdrawal latencies (s) S.E.M., and statistical analysesare performed using a two-way ANOVA followed by Dunnetts test 1.MCE has not independently confirmed the accuracy of

18、these methods. They are for reference only.REFERENCES1. Gougat J, et al. SSR240612 (2R)-2-(3R)-3-(1,3-benzodioxol-5-yl)-3-(6-methoxy-2-naphthyl)sulfonylaminopropanoyl)amino-3-(4-2R,6S)-2,6-dimethylpiperidinylmethylphenyl)-N-isopropyl-N-methylpropanamide hydrochloride, a new nonpeptide antagonist of thebradykinin B1 receptor: biochemical and pharmacological characterization. J Pharmacol Exp Ther. 2004 May;309(2):661-9.2. Dias JP, et al. The kinin B1 receptor antagonist SSR240612 reverses tactile and cold allodynia in an experimental rat

温馨提示

  • 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
  • 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
  • 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
  • 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
  • 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
  • 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
  • 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。

评论

0/150

提交评论